## John D Fraser

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7319206/publications.pdf Version: 2024-02-01



IOHN D FRASER

#	Article	IF	CITATIONS
1	High-affinity binding of staphylococcal enterotoxins A and B to HLA-DR. Nature, 1989, 339, 221-223.	27.8	428
2	The bacterial superantigen and superantigenâ€like proteins. Immunological Reviews, 2008, 225, 226-243.	6.0	415
3	The Staphylococcal Superantigen-Like Protein 7 Binds IgA and Complement C5 and Inhibits IgA-FcαRI Binding and Serum Killing of Bacteria. Journal of Immunology, 2005, 174, 2926-2933.	0.8	237
4	Superantigens – powerful modifiers of the immune system. Trends in Molecular Medicine, 2000, 6, 125-132.	2.6	147
5	Atlas of group A streptococcal vaccine candidates compiled using large-scale comparative genomics. Nature Genetics, 2019, 51, 1035-1043.	21.4	120
6	Status of research and development of vaccines for Streptococcus pyogenes. Vaccine, 2016, 34, 2953-2958.	3.8	113
7	Crystal structure of the streptococcal superantigen SPE-C: dimerization and zinc binding suggest a novel mode of interaction with MHC class II molecules. Nature Structural Biology, 1997, 4, 635-643.	9.7	104
8	Streptococcal superantigens: categorization and clinical associations. Trends in Molecular Medicine, 2014, 20, 48-62.	6.7	97
9	Enterotoxin residues determining T-cell receptor VÎ <sup>2</sup> binding specificity. Nature, 1992, 359, 841-843.	27.8	87
10	The crystal structure of staphylococcal superantigenâ€like protein 11 in complex with sialyl Lewis X reveals the mechanism for cell binding and immune inhibition. Molecular Microbiology, 2007, 66, 1342-1355.	2.5	85
11	The Streptococcal Superantigen Smez Exhibits Wide Allelic Variation, Mosaic Structure, and Significant Antigenic Variation. Journal of Experimental Medicine, 2000, 191, 1765-1776.	8.5	78
12	The Three-dimensional Structure of a Superantigen-like Protein, SET3, from a Pathogenicity Island of the Staphylococcus aureus Genome. Journal of Biological Chemistry, 2002, 277, 32274-32281.	3.4	77
13	The Superantigen Streptococcal Pyrogenic Exotoxin C (SPE-C) Exhibits a Novel Mode of Action. Journal of Experimental Medicine, 1997, 186, 375-383.	8.5	76
14	Specificity of Staphylococcal Superantigen-Like Protein 10 toward the Human IgG1 Fc Domain. Journal of Immunology, 2010, 184, 6283-6292.	0.8	65
15	High Usage of Topical Fusidic Acid and Rapid Clonal Expansion of Fusidic Acid–Resistant Staphylococcus aureus: A Cautionary Tale. Clinical Infectious Diseases, 2014, 59, 1451-1454.	5.8	64
16	Crystal Structures of the Staphylococcal Toxin SSL5 in Complex with Sialyl Lewis X Reveal a Conserved Binding Site that Shares Common Features with Viral and Bacterial Sialic Acid Binding Proteins. Journal of Molecular Biology, 2007, 374, 1298-1308.	4.2	62
17	Characterization of a Mouse-Adapted Staphylococcus aureus Strain. PLoS ONE, 2013, 8, e71142.	2.5	58
18	<i>Staphylococcus aureus</i> regulates the expression and production of the staphylococcal superantigenâ€like secreted proteins in a Rotâ€dependent manner. Molecular Microbiology, 2011, 81, 659-675.	2.5	53

John D Fraser

#	Article	IF	CITATIONS
19	Working towards a Group A Streptococcal vaccine: Report of a collaborative Trans-Tasman workshop. Vaccine, 2014, 32, 3713-3720.	3.8	44
20	Superantigens in human disease. Journal of Clinical Immunology, 1999, 19, 149-157.	3.8	43
21	M-Protein Analysis of Streptococcus pyogenes Isolates Associated with Acute Rheumatic Fever in New Zealand. Journal of Clinical Microbiology, 2015, 53, 3618-3620.	3.9	43
22	Clarifying the Mechanism of Superantigen Toxicity. PLoS Biology, 2011, 9, e1001145.	5.6	42
23	T-Cell Receptor beta-Chain Binding to Enterotoxin Superantigens. Immunological Reviews, 1993, 131, 61-78.	6.0	41
24	An economic case for a vaccine to prevent group A streptococcus skin infections. Vaccine, 2018, 36, 6968-6978.	3.8	41
25	Superantigens: Just Like Peptides Only Different. Journal of Experimental Medicine, 1998, 187, 819-821.	8.5	39
26	Staphylococcal Superantigen Super-Domains in Immune Evasion. Critical Reviews in Immunology, 2010, 30, 149-165.	0.5	38
27	Targeting Antigen to MHC Class II Molecules Promotes Efficient Cross-Presentation and Enhances Immunotherapy. Journal of Immunology, 2009, 182, 1260-1269.	0.8	37
28	Structural and Functional Properties of Staphylococcal Superantigen-Like Protein 4. Infection and Immunity, 2012, 80, 4004-4013.	2.2	33
29	Staphylococcal enterotoxin-like X (SEIX) is a unique superantigen with functional features of two major families of staphylococcal virulence factors. PLoS Pathogens, 2017, 13, e1006549.	4.7	32
30	Comparative M-protein analysis of Streptococcus pyogenes from pharyngitis and skin infections in New Zealand: Implications for vaccine development. BMC Infectious Diseases, 2016, 16, 561.	2.9	25
31	Full functional activity of SSL7 requires binding of both complement C5 and IgA. Immunology and Cell Biology, 2013, 91, 469-476.	2.3	24
32	Development of an opsonophagocytic killing assay for group a streptococcus. Vaccine, 2018, 36, 3756-3763.	3.8	23
33	Clinical development strategy for a candidate group A streptococcal vaccine. Vaccine, 2017, 35, 2007-2014.	3.8	18
34	The economic and health burdens of diseases caused by group A Streptococcus in New Zealand. International Journal of Infectious Diseases, 2021, 103, 176-181.	3.3	18
35	The global response to the COVID-19 pandemic: how have immunology societies contributed?. Nature Reviews Immunology, 2020, 20, 594-602.	22.7	17
36	Enterotoxins can support CAR T cells against solid tumors. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 25229-25235.	7.1	16

JOHN D FRASER

#	Article	IF	CITATIONS
37	An Engineered Non-Toxic Superantigen Increases Cross Presentation of Hepatitis B Virus Nucleocapsids by Human Dendritic Cells. PLoS ONE, 2014, 9, e93598.	2.5	12
38	Synthesis and anti-Helicobacter pylori activity of analogues of spirolaxine methyl ether. MedChemComm, 2012, 3, 938.	3.4	10
39	Synthesis and Biological Evaluation of 7â€Deoxy Analogues of the Human Rhinovirus 3C Protease Inhibitor Thysanone. European Journal of Organic Chemistry, 2014, 2014, 122-128.	2.4	9
40	A potential role for staphylococcal and streptococcal superantigens in driving skewing of TCR Vβ subsets in tonsillar hyperplasia. Medical Microbiology and Immunology, 2017, 206, 337-346.	4.8	9
41	Impact of Superantigen-Producing Bacteria on T Cells from Tonsillar Hyperplasia. Pathogens, 2019, 8, 90.	2.8	9
42	Iridium-Catalysed C–H Borylation Facilitates a Total Synthesis of the HRV 3C Protease Inhibitor (±)-Thysanone. Synlett, 2014, 25, 556-558.	1.8	7
43	Antigen Targeting to Major Histocompatibility Complex Class II with Streptococcal Mitogenic Exotoxin Z-2 M1, a Superantigen-Based Vaccine Carrier. Vaccine Journal, 2012, 19, 574-586.	3.1	6
44	A modified superantigen rescues Ly6Gâ	2.6	5
45	Therapeutic potential of staphylococcal superantigen-like protein 7 for complement-mediated hemolysis. Journal of Molecular Medicine, 2018, 96, 965-974.	3.9	5
46	Superantigen data. Nature, 1992, 360, 423-423.	27.8	4
47	Uncoupling Molecular Testing for SARS-CoV-2 From International Supply Chains. Frontiers in Public Health, 2021, 9, 808751.	2.7	2
48	Bacterial superantigens and immune evasion. , 2003, , 171-200.		1
49	The crystal structure of staphylococcal superantigenâ€ike protein 11 in complex with sialyl Lewis X reveals the mechanism for cell binding and immune inhibition. Molecular Microbiology, 2008, 67, 473-473.	2.5	0

50 The Streptococcal Superantigens. , 0, , 1-20.

0